Compugen Ltd. (NASDAQ:CGEN) was up 6% during trading on Friday . The stock traded as high as $7.48 and last traded at $7.47, with a volume of 314,439 shares trading hands. The stock had previously closed at $7.05.

Several equities research analysts have commented on CGEN shares. FBR & Co reiterated a “buy” rating on shares of Compugen in a research note on Wednesday, June 22nd. Zacks Investment Research raised shares of Compugen from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $10.25.

The company’s market capitalization is $377.23 million. The firm’s 50-day moving average price is $6.80 and its 200-day moving average price is $6.40.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.04. On average, analysts anticipate that Compugen Ltd. will post ($0.56) earnings per share for the current fiscal year.

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.